Company intelligence / Profile preview

Brain Genesis Pharmaceutical

Taipei, Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Brain Genesis Biotechnology is a Taiwanese biopharmaceutical company focused on the development of novel therapeutic formulations derived from traditional Chinese medicine. The company's lead program, BNG-1, is a multi-herb Chinese medicinal formula designed as a non-specific inhibitor of phosphodiesterases (PDEs). BNG-1 has demonstrated significant neuroprotective and anti-inflammatory properties in preclinical models of stroke and non-alcoholic fatty liver disease (NAFLD). By modulating PDE3B expression and reducing oxidative stress, Brain Genesis Biotechnology aims to address metabolic and neurological disorders with high unmet medical needs.

Therapeutic areas: NeurologyEndocrinologyGastroenterology
Modalities: Herbal medicineBotanical extract
Industry: Biotech

Beyond the preview

Go deeper on Brain Genesis Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brain Genesis Pharmaceutical.

Explore the full profile